img

Global Performance Enhancing Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Performance Enhancing Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Performance-enhancing drugs (PED), are substances that are used to improve any form of activity performance in humans.
The global Performance Enhancing Drugs market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
A well-known example of PED involves doping in sport, where banned physical performance–enhancing drugs are used by athletes and bodybuilders. Athletic performance-enhancing substances are sometimes referred to as ergogenic aids. Cognitive performance-enhancing drugs, commonly called nootropics, are sometimes used by students to improve academic performance. Performance-enhancing substances are also used by military personnel to enhance combat performance.
In terms of sales (consumption) side, this report focuses on the sales of Performance Enhancing Drugs by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Performance Enhancing Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Performance Enhancing Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Taj Pharmaceuticals
Balkan Pharmaceuticals
Bayer
AstraZeneca
Novo Nordisk
BrainAlert
Douglas Laboratories
Onnit Labs
Eli Lilly And Company
By Type
Pills
Injections
Patches
By Application
Athletes
Students
Militaries
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Performance Enhancing Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Performance Enhancing Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Performance Enhancing Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Performance Enhancing Drugs Definition
1.2 Market by Type
1.2.1 Global Performance Enhancing Drugs Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Pills
1.2.3 Injections
1.2.4 Patches
1.3 Market Segment by Application
1.3.1 Global Performance Enhancing Drugs Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Athletes
1.3.3 Students
1.3.4 Militaries
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Performance Enhancing Drugs Sales
2.1 Global Performance Enhancing Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Performance Enhancing Drugs Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Performance Enhancing Drugs Revenue by Region
2.3.1 Global Performance Enhancing Drugs Revenue by Region (2018-2023)
2.3.2 Global Performance Enhancing Drugs Revenue by Region (2024-2034)
2.4 Global Performance Enhancing Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Performance Enhancing Drugs Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Performance Enhancing Drugs Sales Quantity by Region
2.6.1 Global Performance Enhancing Drugs Sales Quantity by Region (2018-2023)
2.6.2 Global Performance Enhancing Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Performance Enhancing Drugs Sales Quantity by Manufacturers
3.1.1 Global Performance Enhancing Drugs Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Performance Enhancing Drugs Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Performance Enhancing Drugs Sales in 2024
3.2 Global Performance Enhancing Drugs Revenue by Manufacturers
3.2.1 Global Performance Enhancing Drugs Revenue by Manufacturers (2018-2023)
3.2.2 Global Performance Enhancing Drugs Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Performance Enhancing Drugs Revenue in 2024
3.3 Global Performance Enhancing Drugs Sales Price by Manufacturers
3.4 Global Key Players of Performance Enhancing Drugs, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Performance Enhancing Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Performance Enhancing Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Performance Enhancing Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Performance Enhancing Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Performance Enhancing Drugs Sales Quantity by Type
4.1.1 Global Performance Enhancing Drugs Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Performance Enhancing Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Performance Enhancing Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Performance Enhancing Drugs Revenue by Type
4.2.1 Global Performance Enhancing Drugs Historical Revenue by Type (2018-2023)
4.2.2 Global Performance Enhancing Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Performance Enhancing Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Performance Enhancing Drugs Price by Type
4.3.1 Global Performance Enhancing Drugs Price by Type (2018-2023)
4.3.2 Global Performance Enhancing Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Performance Enhancing Drugs Sales Quantity by Application
5.1.1 Global Performance Enhancing Drugs Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Performance Enhancing Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Performance Enhancing Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Performance Enhancing Drugs Revenue by Application
5.2.1 Global Performance Enhancing Drugs Historical Revenue by Application (2018-2023)
5.2.2 Global Performance Enhancing Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Performance Enhancing Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Performance Enhancing Drugs Price by Application
5.3.1 Global Performance Enhancing Drugs Price by Application (2018-2023)
5.3.2 Global Performance Enhancing Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Performance Enhancing Drugs Sales by Company
6.1.1 North America Performance Enhancing Drugs Revenue by Company (2018-2023)
6.1.2 North America Performance Enhancing Drugs Sales Quantity by Company (2018-2023)
6.2 North America Performance Enhancing Drugs Market Size by Type
6.2.1 North America Performance Enhancing Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Performance Enhancing Drugs Revenue by Type (2018-2034)
6.3 North America Performance Enhancing Drugs Market Size by Application
6.3.1 North America Performance Enhancing Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Performance Enhancing Drugs Revenue by Application (2018-2034)
6.4 North America Performance Enhancing Drugs Market Size by Country
6.4.1 North America Performance Enhancing Drugs Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Performance Enhancing Drugs Revenue by Country (2018-2034)
6.4.3 North America Performance Enhancing Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Performance Enhancing Drugs Sales by Company
7.1.1 Europe Performance Enhancing Drugs Sales Quantity by Company (2018-2023)
7.1.2 Europe Performance Enhancing Drugs Revenue by Company (2018-2023)
7.2 Europe Performance Enhancing Drugs Market Size by Type
7.2.1 Europe Performance Enhancing Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Performance Enhancing Drugs Revenue by Type (2018-2034)
7.3 Europe Performance Enhancing Drugs Market Size by Application
7.3.1 Europe Performance Enhancing Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Performance Enhancing Drugs Revenue by Application (2018-2034)
7.4 Europe Performance Enhancing Drugs Market Size by Country
7.4.1 Europe Performance Enhancing Drugs Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Performance Enhancing Drugs Revenue by Country (2018-2034)
7.4.3 Europe Performance Enhancing Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Performance Enhancing Drugs Sales by Company
8.1.1 China Performance Enhancing Drugs Sales Quantity by Company (2018-2023)
8.1.2 China Performance Enhancing Drugs Revenue by Company (2018-2023)
8.2 China Performance Enhancing Drugs Market Size by Type
8.2.1 China Performance Enhancing Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Performance Enhancing Drugs Revenue by Type (2018-2034)
8.3 China Performance Enhancing Drugs Market Size by Application
8.3.1 China Performance Enhancing Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Performance Enhancing Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Performance Enhancing Drugs Sales by Company
9.1.1 APAC Performance Enhancing Drugs Sales Quantity by Company (2018-2023)
9.1.2 APAC Performance Enhancing Drugs Revenue by Company (2018-2023)
9.2 APAC Performance Enhancing Drugs Market Size by Type
9.2.1 APAC Performance Enhancing Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Performance Enhancing Drugs Revenue by Type (2018-2034)
9.3 APAC Performance Enhancing Drugs Market Size by Application
9.3.1 APAC Performance Enhancing Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Performance Enhancing Drugs Revenue by Application (2018-2034)
9.4 APAC Performance Enhancing Drugs Market Size by Region
9.4.1 APAC Performance Enhancing Drugs Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Performance Enhancing Drugs Revenue by Region (2018-2034)
9.4.3 APAC Performance Enhancing Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Performance Enhancing Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Performance Enhancing Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Performance Enhancing Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Performance Enhancing Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Taj Pharmaceuticals
11.1.1 Taj Pharmaceuticals Company Information
11.1.2 Taj Pharmaceuticals Overview
11.1.3 Taj Pharmaceuticals Performance Enhancing Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Taj Pharmaceuticals Performance Enhancing Drugs Products and Services
11.1.5 Taj Pharmaceuticals Performance Enhancing Drugs SWOT Analysis
11.1.6 Taj Pharmaceuticals Recent Developments
11.2 Balkan Pharmaceuticals
11.2.1 Balkan Pharmaceuticals Company Information
11.2.2 Balkan Pharmaceuticals Overview
11.2.3 Balkan Pharmaceuticals Performance Enhancing Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Balkan Pharmaceuticals Performance Enhancing Drugs Products and Services
11.2.5 Balkan Pharmaceuticals Performance Enhancing Drugs SWOT Analysis
11.2.6 Balkan Pharmaceuticals Recent Developments
11.3 Bayer
11.3.1 Bayer Company Information
11.3.2 Bayer Overview
11.3.3 Bayer Performance Enhancing Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Bayer Performance Enhancing Drugs Products and Services
11.3.5 Bayer Performance Enhancing Drugs SWOT Analysis
11.3.6 Bayer Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Overview
11.4.3 AstraZeneca Performance Enhancing Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 AstraZeneca Performance Enhancing Drugs Products and Services
11.4.5 AstraZeneca Performance Enhancing Drugs SWOT Analysis
11.4.6 AstraZeneca Recent Developments
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Information
11.5.2 Novo Nordisk Overview
11.5.3 Novo Nordisk Performance Enhancing Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Novo Nordisk Performance Enhancing Drugs Products and Services
11.5.5 Novo Nordisk Performance Enhancing Drugs SWOT Analysis
11.5.6 Novo Nordisk Recent Developments
11.6 BrainAlert
11.6.1 BrainAlert Company Information
11.6.2 BrainAlert Overview
11.6.3 BrainAlert Performance Enhancing Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 BrainAlert Performance Enhancing Drugs Products and Services
11.6.5 BrainAlert Performance Enhancing Drugs SWOT Analysis
11.6.6 BrainAlert Recent Developments
11.7 Douglas Laboratories
11.7.1 Douglas Laboratories Company Information
11.7.2 Douglas Laboratories Overview
11.7.3 Douglas Laboratories Performance Enhancing Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Douglas Laboratories Performance Enhancing Drugs Products and Services
11.7.5 Douglas Laboratories Performance Enhancing Drugs SWOT Analysis
11.7.6 Douglas Laboratories Recent Developments
11.8 Onnit Labs
11.8.1 Onnit Labs Company Information
11.8.2 Onnit Labs Overview
11.8.3 Onnit Labs Performance Enhancing Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Onnit Labs Performance Enhancing Drugs Products and Services
11.8.5 Onnit Labs Performance Enhancing Drugs SWOT Analysis
11.8.6 Onnit Labs Recent Developments
11.9 Eli Lilly And Company
11.9.1 Eli Lilly And Company Company Information
11.9.2 Eli Lilly And Company Overview
11.9.3 Eli Lilly And Company Performance Enhancing Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Eli Lilly And Company Performance Enhancing Drugs Products and Services
11.9.5 Eli Lilly And Company Performance Enhancing Drugs SWOT Analysis
11.9.6 Eli Lilly And Company Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Performance Enhancing Drugs Value Chain Analysis
12.2 Performance Enhancing Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Performance Enhancing Drugs Production Mode & Process
12.4 Performance Enhancing Drugs Sales and Marketing
12.4.1 Performance Enhancing Drugs Sales Channels
12.4.2 Performance Enhancing Drugs Distributors
12.5 Performance Enhancing Drugs Customers
13 Market Dynamics
13.1 Performance Enhancing Drugs Industry Trends
13.2 Performance Enhancing Drugs Market Drivers
13.3 Performance Enhancing Drugs Market Challenges
13.4 Performance Enhancing Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Pills
Table 3. Major Manufacturers of Injections
Table 4. Major Manufacturers of Patches
Table 5. Global Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Performance Enhancing Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Performance Enhancing Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Performance Enhancing Drugs Revenue Market Share by Region (2018-2023)
Table 9. Global Performance Enhancing Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Performance Enhancing Drugs Revenue Market Share by Region (2024-2034)
Table 11. Global Performance Enhancing Drugs Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 12. Global Performance Enhancing Drugs Sales by Region (2018-2023) & (K Units)
Table 13. Global Performance Enhancing Drugs Sales Market Share by Region (2018-2023)
Table 14. Global Performance Enhancing Drugs Sales by Region (2024-2034) & (K Units)
Table 15. Global Performance Enhancing Drugs Sales Market Share by Region (2024-2034)
Table 16. Global Performance Enhancing Drugs Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 17. Global Performance Enhancing Drugs Sales Quantity Share by Manufacturers (2018-2023)
Table 18. Global Performance Enhancing Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 19. Global Performance Enhancing Drugs Revenue Share by Manufacturers (2018-2023)
Table 20. Global Performance Enhancing Drugs Price by Manufacturers 2018-2023 (USD/Unit)
Table 21. Global Key Players of Performance Enhancing Drugs, Industry Ranking, 2021 VS 2024
Table 22. Global Performance Enhancing Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Performance Enhancing Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Performance Enhancing Drugs as of 2024)
Table 24. Global Key Manufacturers of Performance Enhancing Drugs, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Performance Enhancing Drugs, Product Offered and Application
Table 26. Global Key Manufacturers of Performance Enhancing Drugs, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Performance Enhancing Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 29. Global Performance Enhancing Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 30. Global Performance Enhancing Drugs Sales Quantity Share by Type (2018-2023)
Table 31. Global Performance Enhancing Drugs Sales Quantity Share by Type (2024-2034)
Table 32. Global Performance Enhancing Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 33. Global Performance Enhancing Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Performance Enhancing Drugs Revenue Share by Type (2018-2023)
Table 35. Global Performance Enhancing Drugs Revenue Share by Type (2024-2034)
Table 36. Performance Enhancing Drugs Price by Type (2018-2023) & (USD/Unit)
Table 37. Global Performance Enhancing Drugs Price Forecast by Type (2024-2034) & (USD/Unit)
Table 38. Global Performance Enhancing Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 39. Global Performance Enhancing Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 40. Global Performance Enhancing Drugs Sales Quantity Share by Application (2018-2023)
Table 41. Global Performance Enhancing Drugs Sales Quantity Share by Application (2024-2034)
Table 42. Global Performance Enhancing Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 43. Global Performance Enhancing Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Performance Enhancing Drugs Revenue Share by Application (2018-2023)
Table 45. Global Performance Enhancing Drugs Revenue Share by Application (2024-2034)
Table 46. Performance Enhancing Drugs Price by Application (2018-2023) & (USD/Unit)
Table 47. Global Performance Enhancing Drugs Price Forecast by Application (2024-2034) & (USD/Unit)
Table 48. North America Performance Enhancing Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 49. North America Performance Enhancing Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 50. North America Performance Enhancing Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 51. North America Performance Enhancing Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 52. North America Performance Enhancing Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 53. North America Performance Enhancing Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Performance Enhancing Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 55. North America Performance Enhancing Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 56. North America Performance Enhancing Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 57. North America Performance Enhancing Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Performance Enhancing Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 59. North America Performance Enhancing Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 60. North America Performance Enhancing Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Performance Enhancing Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 62. North America Performance Enhancing Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 63. Europe Performance Enhancing Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 64. Europe Performance Enhancing Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 65. Europe Performance Enhancing Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 66. Europe Performance Enhancing Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 67. Europe Performance Enhancing Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 68. Europe Performance Enhancing Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Performance Enhancing Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 70. Europe Performance Enhancing Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 71. Europe Performance Enhancing Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 72. Europe Performance Enhancing Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Performance Enhancing Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 74. Europe Performance Enhancing Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 75. Europe Performance Enhancing Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Performance Enhancing Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 77. Europe Performance Enhancing Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 78. China Performance Enhancing Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 79. China Performance Enhancing Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 80. China Performance Enhancing Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 81. China Performance Enhancing Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 82. China Performance Enhancing Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 83. China Performance Enhancing Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Performance Enhancing Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 85. China Performance Enhancing Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 86. China Performance Enhancing Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 87. China Performance Enhancing Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Performance Enhancing Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 89. APAC Performance Enhancing Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 90. APAC Performance Enhancing Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 91. APAC Performance Enhancing Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 92. APAC Performance Enhancing Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 93. APAC Performance Enhancing Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Performance Enhancing Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 95. APAC Performance Enhancing Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 96. APAC Performance Enhancing Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 97. APAC Performance Enhancing Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Performance Enhancing Drugs Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 99. APAC Performance Enhancing Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 100. APAC Performance Enhancing Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Performance Enhancing Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 102. APAC Performance Enhancing Drugs Sales Quantity by Region (2024-2034) & (K Units)
Table 103. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Company (2018-2023) & (K Units)
Table 104. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 105. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 106. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Type (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Application (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 117. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 118. Taj Pharmaceuticals Company Information
Table 119. Taj Pharmaceuticals Description and Overview
Table 120. Taj Pharmaceuticals Performance Enhancing Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 121. Taj Pharmaceuticals Performance Enhancing Drugs Product and Services
Table 122. Taj Pharmaceuticals Performance Enhancing Drugs SWOT Analysis
Table 123. Taj Pharmaceuticals Recent Developments
Table 124. Balkan Pharmaceuticals Company Information
Table 125. Balkan Pharmaceuticals Description and Overview
Table 126. Balkan Pharmaceuticals Performance Enhancing Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 127. Balkan Pharmaceuticals Performance Enhancing Drugs Product and Services
Table 128. Balkan Pharmaceuticals Performance Enhancing Drugs SWOT Analysis
Table 129. Balkan Pharmaceuticals Recent Developments
Table 130. Bayer Company Information
Table 131. Bayer Description and Overview
Table 132. Bayer Performance Enhancing Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 133. Bayer Performance Enhancing Drugs Product and Services
Table 134. Bayer Performance Enhancing Drugs SWOT Analysis
Table 135. Bayer Recent Developments
Table 136. AstraZeneca Company Information
Table 137. AstraZeneca Description and Overview
Table 138. AstraZeneca Performance Enhancing Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 139. AstraZeneca Performance Enhancing Drugs Product and Services
Table 140. AstraZeneca Performance Enhancing Drugs SWOT Analysis
Table 141. AstraZeneca Recent Developments
Table 142. Novo Nordisk Company Information
Table 143. Novo Nordisk Description and Overview
Table 144. Novo Nordisk Performance Enhancing Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 145. Novo Nordisk Performance Enhancing Drugs Product and Services
Table 146. Novo Nordisk Performance Enhancing Drugs SWOT Analysis
Table 147. Novo Nordisk Recent Developments
Table 148. BrainAlert Company Information
Table 149. BrainAlert Description and Overview
Table 150. BrainAlert Performance Enhancing Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 151. BrainAlert Performance Enhancing Drugs Product and Services
Table 152. BrainAlert Performance Enhancing Drugs SWOT Analysis
Table 153. BrainAlert Recent Developments
Table 154. Douglas Laboratories Company Information
Table 155. Douglas Laboratories Description and Overview
Table 156. Douglas Laboratories Performance Enhancing Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 157. Douglas Laboratories Performance Enhancing Drugs Product and Services
Table 158. Douglas Laboratories Performance Enhancing Drugs SWOT Analysis
Table 159. Douglas Laboratories Recent Developments
Table 160. Onnit Labs Company Information
Table 161. Onnit Labs Description and Overview
Table 162. Onnit Labs Performance Enhancing Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 163. Onnit Labs Performance Enhancing Drugs Product and Services
Table 164. Onnit Labs Performance Enhancing Drugs SWOT Analysis
Table 165. Onnit Labs Recent Developments
Table 166. Eli Lilly And Company Company Information
Table 167. Eli Lilly And Company Description and Overview
Table 168. Eli Lilly And Company Performance Enhancing Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 169. Eli Lilly And Company Performance Enhancing Drugs Product and Services
Table 170. Eli Lilly And Company Performance Enhancing Drugs SWOT Analysis
Table 171. Eli Lilly And Company Recent Developments
Table 172. Key Raw Materials Lists
Table 173. Raw Materials Key Suppliers Lists
Table 174. Performance Enhancing Drugs Distributors List
Table 175. Performance Enhancing Drugs Customers List
Table 176. Performance Enhancing Drugs Market Trends
Table 177. Performance Enhancing Drugs Market Drivers
Table 178. Performance Enhancing Drugs Market Challenges
Table 179. Performance Enhancing Drugs Market Restraints
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
List of Figures
Figure 1. Performance Enhancing Drugs Product Picture
Figure 2. Global Performance Enhancing Drugs Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Performance Enhancing Drugs Market Share by Type in 2024 & 2034
Figure 4. Pills Product Picture
Figure 5. Injections Product Picture
Figure 6. Patches Product Picture
Figure 7. Global Performance Enhancing Drugs Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 8. Global Performance Enhancing Drugs Market Share by Application in 2024 & 2034
Figure 9. Athletes
Figure 10. Students
Figure 11. Militaries
Figure 12. Others
Figure 13. Performance Enhancing Drugs Report Years Considered
Figure 14. Global Performance Enhancing Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 15. Global Performance Enhancing Drugs Revenue 2018-2034 (US$ Million)
Figure 16. Global Performance Enhancing Drugs Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 17. Global Performance Enhancing Drugs Sales Quantity 2018-2034 (K Units)
Figure 18. Global Performance Enhancing Drugs Sales Quantity Market Share by Region (2018-2023)
Figure 19. Global Performance Enhancing Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Performance Enhancing Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. North America Performance Enhancing Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Performance Enhancing Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. Europe Performance Enhancing Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Performance Enhancing Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. China Performance Enhancing Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Performance Enhancing Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. APAC Performance Enhancing Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Performance Enhancing Drugs Sales Quantity in 2024
Figure 31. The Top 10 and Top 5 Players Market Share by Performance Enhancing Drugs Revenue in 2024
Figure 32. Performance Enhancing Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 33. Global Performance Enhancing Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Performance Enhancing Drugs Revenue Market Share by Type (2018-2034)
Figure 35. Global Performance Enhancing Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Performance Enhancing Drugs Revenue Market Share by Application (2018-2034)
Figure 37. North America Performance Enhancing Drugs Revenue Market Share by Company in 2024
Figure 38. North America Performance Enhancing Drugs Sales Quantity Market Share by Company in 2024
Figure 39. North America Performance Enhancing Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Performance Enhancing Drugs Revenue Market Share by Type (2018-2034)
Figure 41. North America Performance Enhancing Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Performance Enhancing Drugs Revenue Market Share by Application (2018-2034)
Figure 43. North America Performance Enhancing Drugs Revenue Share by Country (2018-2034)
Figure 44. North America Performance Enhancing Drugs Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Performance Enhancing Drugs Sales Quantity Market Share by Company in 2024
Figure 48. Europe Performance Enhancing Drugs Revenue Market Share by Company in 2024
Figure 49. Europe Performance Enhancing Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Performance Enhancing Drugs Revenue Market Share by Type (2018-2034)
Figure 51. Europe Performance Enhancing Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Performance Enhancing Drugs Revenue Market Share by Application (2018-2034)
Figure 53. Europe Performance Enhancing Drugs Revenue Share by Country (2018-2034)
Figure 54. Europe Performance Enhancing Drugs Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 56. France Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 60. China Performance Enhancing Drugs Sales Quantity Market Share by Company in 2024
Figure 61. China Performance Enhancing Drugs Revenue Market Share by Company in 2024
Figure 62. China Performance Enhancing Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Performance Enhancing Drugs Revenue Market Share by Type (2018-2034)
Figure 64. China Performance Enhancing Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Performance Enhancing Drugs Revenue Market Share by Application (2018-2034)
Figure 66. APAC Performance Enhancing Drugs Sales Quantity Market Share by Company in 2024
Figure 67. APAC Performance Enhancing Drugs Revenue Market Share by Company in 2024
Figure 68. APAC Performance Enhancing Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Performance Enhancing Drugs Revenue Market Share by Type (2018-2034)
Figure 70. APAC Performance Enhancing Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Performance Enhancing Drugs Revenue Market Share by Application (2018-2034)
Figure 72. APAC Performance Enhancing Drugs Revenue Share by Region (2018-2034)
Figure 73. APAC Performance Enhancing Drugs Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 78. India Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity Market Share by Company in 2024
Figure 80. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue Market Share by Company in 2024
Figure 81. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Performance Enhancing Drugs Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Performance Enhancing Drugs Revenue Share by Country (2018-2034)
Figure 87. Brazil Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Performance Enhancing Drugs Revenue (2018-2034) & (US$ Million)
Figure 92. Performance Enhancing Drugs Value Chain
Figure 93. Performance Enhancing Drugs Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed